drugset / Trial / NCT02044393

Interaction of BI 691751 With Itraconazole

NCT02044393 ↗

Phase 1 Completed 20 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

Investigation of the relative bioavailability of a single dose of BI 691751 when given alone and together with itraconazole; safety and tolerability

Timeline

Start
2014-01
Primary completion
2014-05
Completion
2014-05

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 691751 Unknown — Oral
Subject Itraconazole Small molecule — Oral

Indications

No indication recorded.